Background and Importance Migraine is a highly disabling chronic disease. Erenumab is a preventive treatment to reduce frequency, intensity and duration of migraine crises, to improve the quality of life, reducing the impact of the disease on the functionality of the patient.

Aim and Objectives The aim was to evaluate the quality of life perceived by the patient before starting treatment with erenumab and after 12 months.

Material and Methods Prospective observational study which includes patients with chronic or episodic high-frequency migraine treated with erenumab (August 2020 to December 2022), who had completed 12 months of treatment.

Demographic data (sex; age), clinical data (type of migraine; monthly migraine days and intensity at the beginning of treatment and 12 months after) were collected and EuroQol-Questionnaire was performed to assess quality of life at the beginning and 12 months after.

With EQ-5D-5L-Questionnaire, patients evaluate his own health status. Crosswalk Index Value Calculator and SPSS-Statistics v28.0.1.1 were used for the health status calculation.

Results We analysed 32 patients with a median age of 52 years (IQR: 46.45–59.4) being 27 women. Twenty-eight of them were diagnosed with chronic migraine and four with high frequency episodic migraine. Two patients stopped treatment before 12 months due to lack of response (excluded from the analysis).

Average reduction in monthly migraines was 10.75 days (7.07–14.42). Mean migraines intensity before treatment was 8.6 (7.97–9.3); and 5.28 (4.18–6.37) after. Number of patients who report not having problems related to mobility, personal care, daily activities, pain/discomfort and anxiety/depression has increased and/or maintained after 12 months of treatment compared to baseline: 18 vs 21; 23 vs 23; 9 vs 18; 3 vs 12; and 6 vs 11, respectively. Mean according to EQ-5D-questionnaire before erenumab was 0.5694 (-0.008–1) and 0.7198 (-0.096–1) after. Improvement of quality life was considered statistically significant (p<0.01). Mean value of EVA scale before treatment was 50% (10–95%) and 68.5% (15–100%) after. Improvement in quality of life is considered statistically significant (p=0.008).

Conclusion and Relevance It is important to carry out studies that include greater sample, but in our experience treatment with erenumab has been a great improvement in quality life of patients with migraine, thus reducing the impact of their disease in their day to day.

References and/or Acknowledgements 1. Eur J Neurol. 2021 May;28(5):1716–1725.

Conflict of Interest No conflict of interest.